Invesco’s Neuropace NPCE Stock Holding History

Invesco’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$140K	Sell	10,674 -1,265	-11%	-$19K	﹤0.01%	3580
2025 Q4	$184K	Buy	+11,939	New	+$160K	﹤0.01%	3550

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco's NPCE Position: Q1 2026 in Review

Invesco reduced its Neuropace (NPCE) stake by 11% in Q1 2026, selling an estimated $19K and leaving 10,674 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #3580.

Invesco first reported a position in NPCE in Q4 2025 and has held it in 2 quarters since. The position peaked at $184K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

Invesco held 10,674 shares of Neuropace worth $140K as of Q1 2026.
Invesco sold 1,265 Neuropace shares in Q1 2026, an estimated $19K.
Neuropace made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3580 holding.
Invesco first reported a position in Neuropace in Q4 2025 and has held it in 2 quarters since.
Invesco's Neuropace position peaked at $184K in Q4 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.